Michael L. Riordan
Co-founder 1987Background
Michael L. Riordan founded Gilead Sciences in 1987 with an initial focus on developing antifungal therapies for life-threatening infections. His defining moment was the decision to execute a desperate initial public offering in 1992 when the company was on the brink of bankruptcy, raising $86 million and providing the necessary lifeline to continue operations and pivot to antivirals. This decision established the company's long-term philosophy of taking calculated scientific risks to bring novel, life-saving therapies to patients with limited treatment options.
Role at Gilead Sciences, Inc.
Gilead Sciences possesses an academic, mission-driven founding story, rooted in the uncertainty of the early HIV/AIDS epidemic and the ambitious application of emerging antiviral science. The company was founded in 1987 in Foster City, California, by Dr. Michael Riordan. Riordan was brilliant, holding degrees from both Washington University and Johns Hopkins School of Medicine, and he had also worked in venture capital. When he founded Gilead (at just 29 years old), the biotech landscape was heavily dominated by companies focusing on proteins and complex antibodies. Riordan, however, had a personal and foundational focus: antivirals. Having survived a severe bout of dengue fever while working in a clinic in the Philippines he was obsessed with developing drugs that could stop deadly viruses from replicating. He founded Gilead (named after the 'Balm of Gilead,' a healing ointment from the Bible) with exactly $2 million in venture capital. The early years were intensely difficult, characterized by scientific failures and a complete lack of revenue. However, the foundational masterstroke occurred in the 1990s when Gilead developed expertise in nucleotide analogs—compounds that essentially mimic the building blocks of DNA to trick and destroy viruses. This scientific breakthrough culminated in the development of Tenofovir, the foundational drug for the modern treatment of HIV. By focusing on complex, targeted antivirals rather than chasing broader biotech trends, Riordan established the foundational architecture that eventually allowed Gilead to revolutionize the treatment of HIV, Hepatitis B, and eventually Hepatitis C, cementing its status as one of the most impactful pharmaceutical companies in modern history.